Nektar Therapeutics (NKTR) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Nektar Therapeutics (NKTR)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.92

0.02 (2.22%)

At close: Jan 15, 2025, 1:56 PM

undefined% (undefined)

Bid	0.92
Market Cap	169.35M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.84
PE Ratio (ttm)	-1.09
Forward PE	n/a
Analyst	Buy

Ask	0.92
Volume	787,348
Avg. Volume (20D)	1,886,895
Open	0.93
Previous Close	0.90
Day's Range	0.90 - 0.95
52-Week Range	0.48 - 1.93
Beta	undefined

About NKTR

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and a...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 3, 1994

Employees 137

Stock Exchange NASDAQ

Ticker Symbol NKTR

Website https://www.nektar.com

Analyst Forecast

According to 5 analyst ratings, the average rating for NKTR stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 335.68% from the latest price.

Buy 80.00%

Hold 20.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Nektar Therapeutics is scheduled to release its earnings on Mar 3, 2025, during market hours.
Analysts project revenue of $36.65M, reflecting a 53.44% YoY growth and earnings per share of -0.19, making a -13.64% decrease YoY.

Why Price Moved

2 months ago · Source

+8.13%

Nektar Therapeutics shares are trading higher afte... Unlock content with Pro Subscription

8 months ago · Source

+10%

Nektar Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.

News

2 months ago · seekingalpha.com

Multiple Catalysts Ahead For Nektar Therapeutics

Nektar continues to make progress with rezpegaldesleukin, with results from the phase 2 atopic dermatitis study expected in H1'25. NKTR-255 is showing promising results in multiple oncology trials, al...

2 months ago · zacks.com

Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus

NKTR reports encouraging third-quarter results as both earnings and revenues beat estimates. Product sales increase year over year.

2 months ago · zacks.com

Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates

Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.19 per share a year ago.

2 months ago · benzinga.com

Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential

Piper Sandler has initiated coverage on Nektar Therapeutics Inc NKTR, citing the company's lead asset rezpegaldesleukin's (REZPEG) differentiated mechanism of action.